AbbVie Q2 adjusted EPS $2.97 (+12.1%); raises FY 2025 guidance to $11.88-$12.08

AbbVie Inc.

2025-Q2 EPS reported $1.24 vs consensus $2.94 ▼ miss (-57.9%)

Q2 GAAP EPS $0.52 (down 32.5%); adjusted EPS $2.97 (+12.1%); revenue $15.423B (+6.6%).
Immunology revenue $7.631B (+9.5%); Skyrizi $4.423B (+62.2%), Rinvoq $2.028B (+41.8%), Humira $1.180B (-58.1%).
FY 2025 adjusted EPS guidance raised from $11.67-$11.87 to $11.88-$12.08; includes $0.55 IPR&D impact.
Agreed to acquire Capstan Therapeutics (anti-CD19 CAR-T for autoimmune diseases); terms not disclosed.
FDA approved Rinvoq for giant cell arteritis; Emrelis accelerated approval for c-Met high NSCLC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.